Download PDF
Klinische Neurophysiologie 2014; 45(04): 214-221
DOI: 10.1055/s-0034-1390464
Originalia
© Georg Thieme Verlag KG Stuttgart · New York

Autoimmune Enzephalitiden

Autoimmune Encephalitis
R. Weissert
1   Neurologische Klinik und Poliklinik am Bezirksklinikum, Universität Regensburg
› Author Affiliations
Further Information

Publication History

Publication Date:
22 December 2014 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Autoimmune Enzephalitiden können durch Autoimmunreaktionen gegen extrazellulär auf Nervenzellen exprimierte Proteine oder gegen intrazellulär oder/und nukleär lokalisierte Proteine verursacht werden. Bisher sind bereits etwa 20 verschiedene Autoantigene beschrieben worden, die bei einer autoimmunen Enzephalitis die Zielstrukturen für die adaptive Immunantwort (T Zellen, B Zellen, Autoantikörper) sind. Ein Teil der Enzephalitiden kann eine paraneoplastische Ursache haben. Die Diagnose ist häufig schwierig zu finden, da die Symptome viele zerebrale Funktionssysteme betreffen, Erkrankungen aus dem klassischen psychiatrischen Formenkreis imitieren können und der Diagnoseaufwand hoch ist. Die Therapie sollte abhängig von dem der Erkrankung zu Grunde liegenden immunologischen Pathomechanismus gewählt werden und bei paraneoplastischen Formen ist zudem die Behandlung des zugrundeliegenden Tumorleidens unumgänglich.

Abstract

Autoimmune encephalitis can be caused by autoimmune reactions against extracellular proteins expressed on nerve cells or against intracellular or/and nuclear localised proteins. Up to now about 20 different autoantigens have been described that can be the target structures for the adaptive immune response (T cells, B cells, autoantibodies). Some of the autoimmune encephalitis forms can have a paraneoplastic origin. The diagnosis is often difficult because the symptoms can arise from multiple cerebral functional systems and can imitate those of classic psychiatric diseases so that the diagnostic effort and cost can be high. The therapeutic approach depends on the underlying immunological pathomechanisms and in the case of paraneoplastic forms, therapy for the underlying malignancy is mandatory.

Schlüsselwörter

Autoimmune Enzephalitis - paraneoplastisch - Autoantigen - Neuron - Immuntherapie

Key words

autoimmune encephalitis - paraneoplastic - autoantigen - neuron - immune therapy
 

  • Literatur

  • 1 Granerod J, Ambrose HE, Davies NW et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 2010; 10: 835-844
    CrossrefPubMedGoogle Scholar
  • 2 Gable MS, Gavali S, Radner A et al. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol Infect Dis 2009; 28: 1421-1429
    CrossrefPubMedGoogle Scholar
  • 3 Vincent A, Bien CG, Irani SR et al. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011; 10: 759-772
    CrossrefPubMedGoogle Scholar
  • 4 Machado S, Pinto AN, Irani SR. What should you know about limbic encephalitis?. Arq Neuropsiquiatr 2012; 70: 817-822
    CrossrefPubMedGoogle Scholar
  • 5 Lennox BR, Coles AJ, Vincent A. Antibody-mediated encephalitis: a treatable cause of schizophrenia. Br J Psychiatry 2012; 200: 92-94
    CrossrefPubMedGoogle Scholar
  • 6 Hammer C, Stepniak B, Schneider A et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol Psychiatry 2013; DOI: 10.1038/mp.2013.110.
    PubMedGoogle Scholar
  • 7 Titulaer MJ, Dalmau J. Antibodies to NMDA receptor, blood-brain barrier disruption and schizophrenia: a theory with unproven links. Mol Psychiatry 2014; DOI: 10.1038/mp.2014.25.
    PubMedGoogle Scholar
  • 8 Roberts WK, Deluca IJ, Thomas A et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest 2009; 119: 2042-2051
    PubMedGoogle Scholar
  • 9 Dahm L, Ott C, Steiner J et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol 2014; DOI: 10.1002/ana.24189.
    PubMedGoogle Scholar
  • 10 Dalmau J, Lancaster E, Martinez-Hernandez E et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63-74
    Google Scholar
  • 11 Irani SR, Bera K, Waters P et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010; 133: 1655-1667
    CrossrefPubMedGoogle Scholar
  • 12 Vincent A, Bien CG. Anti-NMDA-receptor encephalitis: a cause of psychiatric, seizure, and movement disorders in young adults. Lancet Neurol 2008; 7: 1074-1075
    CrossrefPubMedGoogle Scholar
  • 13 Moscato EH, Peng X, Jain A et al. Acute mechanisms underlying antibody effects in anti-NMDA receptor encephalitis. Ann Neurol 2014; DOI: 10.1002/ana.24195.
    PubMedGoogle Scholar
  • 14 Titulaer MJ, Hoftberger R, Iizuka T et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014; 75: 411-428
    CrossrefPubMedGoogle Scholar
  • 15 Gresa-Arribas N, Titulaer MJ, Torrents A et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014; 13: 167-177
    CrossrefPubMedGoogle Scholar
  • 16 Titulaer MJ, McCracken L, Gabilondo I et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12: 157-165
    CrossrefPubMedGoogle Scholar
  • 17 Lancaster E, Lai M, Peng X et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010; 9: 67-76
    CrossrefPubMedGoogle Scholar
  • 18 Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011; 77: 179-189
    CrossrefPubMedGoogle Scholar
  • 19 Petit-Pedrol M, Armangue T, Peng X et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014; 13: 276-286
    CrossrefPubMedGoogle Scholar
  • 20 Irani SR, Michell AW, Lang B et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011; 69: 892-900
    CrossrefPubMedGoogle Scholar
  • 21 Irani SR, Alexander S, Waters P et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 2010; 133: 2734-2748
    CrossrefPubMedGoogle Scholar
  • 22 Lai M, Huijbers MG, Lancaster E et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9: 776-785
    CrossrefPubMedGoogle Scholar
  • 23 Kalachikov S, Evgrafov O, Ross B et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat Genet 2002; 30: 335-341
    CrossrefPubMedGoogle Scholar
  • 24 Irani SR, Buckley C, Vincent A et al. Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology 2008; 71: 1647-1648
    CrossrefPubMedGoogle Scholar
  • 25 Vincent A, Buckley C, Schott JM et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127: 701-712
    CrossrefPubMedGoogle Scholar
  • 26 Boronat A, Gelfand JM, Gresa-Arribas N et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol 2013; 73: 120-128
    CrossrefPubMedGoogle Scholar
  • 27 Lancaster E, Martinez-Hernandez E, Titulaer MJ et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 2011; 77: 1698-1701
    CrossrefPubMedGoogle Scholar
  • 28 Graus F, Arino H, Dalmau J. Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood 2014; 123: 3230-3238
    CrossrefPubMedGoogle Scholar
  • 29 Hutchinson M, Waters P, McHugh J et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 2008; 71: 1291-1292
    CrossrefPubMedGoogle Scholar
  • 30 Okano HJ, Darnell RB. A hierarchy of Hu RNA binding proteins in developing and adult neurons. J Neurosci 1997; 17: 3024-3037
    PubMedGoogle Scholar
  • 31 Dalmau J, Graus F, Rosenblum MK et al. Anti-Hu–associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine 1992; 71: 59-72
    CrossrefPubMedGoogle Scholar
  • 32 Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003; 349: 1543-1554
    CrossrefPubMedGoogle Scholar
  • 33 Greenlee JE, Brashear HR. Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann Neurol 1983; 14: 609-613
    CrossrefPubMedGoogle Scholar
  • 34 Jaeckle KA, Graus F, Houghton A et al. Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen. Ann Neurol 1985; 18: 592-600
    CrossrefPubMedGoogle Scholar
  • 35 Yamashita N, Mosinger B, Roy A et al. CRMP5 (collapsin response mediator protein 5) regulates dendritic development and synaptic plasticity in the cerebellar Purkinje cells. J Neurosci 2011; 31: 1773-1779
    CrossrefPubMedGoogle Scholar
  • 36 Monstad SE, Nostbakken JK, Vedeler CA. CRMP5 antibodies found in a patient with limbic encephalitis and myasthenia gravis. J Neurol Neurosurg Psychiatry 2009; 80: 241-242
    CrossrefPubMedGoogle Scholar
  • 37 Antoine JC, Absi L, Honnorat J et al. Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol 1999; 56: 172-177
    CrossrefPubMedGoogle Scholar
  • 38 Jensen KB, Dredge BK, Stefani G et al. Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability. Neuron 2000; 25: 359-371
    CrossrefPubMedGoogle Scholar
  • 39 Buckanovich RJ, Posner JB, Darnell RB. Nova the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron 1993; 11: 657-672
    CrossrefPubMedGoogle Scholar
  • 40 Luque FA, Furneaux HM, Ferziger R et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991; 29: 241-251
    CrossrefPubMedGoogle Scholar
  • 41 Dalmau J, Gultekin SH, Voltz R et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 1999; 122: 27-39
    CrossrefPubMedGoogle Scholar
  • 42 Voltz R, Gultekin SH, Rosenfeld MR et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 1999; 340: 1788-1795
    CrossrefPubMedGoogle Scholar
  • 43 Dalmau J, Graus F, Villarejo A et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127: 1831-1844
    CrossrefPubMedGoogle Scholar
  • 44 Bataller L, Wade DF, Graus F et al. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 2004; 62: 778-782
    CrossrefPubMedGoogle Scholar
  • 45 Pruss H, Finke C, Holtje M et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 2012; 72: 902-911
    CrossrefPubMedGoogle Scholar
  • 46 Armangue T, Leypoldt F, Malaga I et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 2014; 75: 317-323
    CrossrefPubMedGoogle Scholar
  • 47 Hargrave DR, Webb DW. Movement disorders in association with herpes simplex virus encephalitis in children: a review. Dev Med Child Neurol 1998; 40: 640-642
    PubMedGoogle Scholar
  • 48 De Tiege X, Rozenberg F, Des Portes V et al. Herpes simplex encephalitis relapses in children: differentiation of two neurologic entities. Neurology 2003; 61: 241-243
    CrossrefPubMedGoogle Scholar
  • 49 Irani SR, Vincent A. The expanding spectrum of clinically-distinctive, immunotherapy-responsive autoimmune encephalopathies. Arq Neuropsiquiatr 2012; 70: 300-304
    CrossrefPubMedGoogle Scholar
  • 50 Brown JW, Martin PJ, Thorpe JW et al. Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis. J Neuroimmunol 2014; 271: 66-68
    CrossrefPubMedGoogle Scholar